Takeda’s Alogliptin Strategy: Treatment Options
This article was originally published in PharmAsia News
Executive Summary
With patent protection for its blockbuster insulin-resistance drug Actos (pioglitazone) set to expire in 2011, Takeda is testing its new Type 2 diabetes candidate, alogliptin, in several therapeutic settings to give physicians confidence the drug will fit into a variety of treatment plans
You may also be interested in...
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said
AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
Deal is “natural progression” of two companies collaborations; dapagliflozin is currently in Phase II trials in Japan and Phase III in the U.S.